Tweet
Hong Kong, Case of NDM-4 Carbapenemase-producing Enterobacteriaceae under CHP investigation (June 13 2013): 28th case
[Source: Centre for Health Protection, Hong Kong PRC SAR, full text: (LINK).]
Case of NDM-4 Carbapenemase-producing Enterobacteriaceae under CHP investigation
The Public Health Laboratory Services Branch (PHLSB) of the Centre for Health Protection (CHP) of the Department of Health confirmed today (June 13) a case of New Delhi metallo-β-lactamase-4 (NDM-4) Carbapenemase-producing Enterobacteriaceae in a 95-year-old man.
The patient, with chronic illnesses, travelled to India in February and developed urinary symptoms by late February. He sought local medical attention without hospitalisation. Upon arrival in Hong Kong in May he attended the Accident and Emergency Department of Queen Mary Hospital on May 26 and June 4 and no hospitalisation was required.
The clinical diagnosis was urinary tract infection. His condition has been stable all along.
The patient's urine specimen grew NDM-4 Carbapenemase-producing Enterobacteriaceae as confirmed by the PHLSB.
His family contacts remained asymptomatic. The CHP's investigation is proceeding.
This is the 28th detected case of NDM Carbapenemase-producing Enterobacteriaceae in Hong Kong.
NDM is an enzyme which can inactivate carbapenems and other beta-lactams such as penicillins. Bacteria harbouring this NDM gene are commonly resistant to multiple antimicrobials, limiting therapeutic options and rendering severe clinical infections difficult to treat. Most bacteria with the NDM enzyme remain susceptible to two types of antibiotics, colistin and tigecycline.
Infections have varied from being asymptomatic to potentially life-threatening or fatal. The level of risk depends on which part of the body is affected by the infection, and the general health of the patient.
NDM-producing Enterobacteriaceae was first reported in a Swedish patient of Indian origin who travelled to New Delhi, India, in 2008. The first fatal case was identified in 2010 in a patient who received medical treatment in Pakistan before being repatriated to Belgium.
NDM-producing Enterobacteriaceae has now been reported in many countries and regions including Australia, Austria, Canada, Belgium, France, Germany, Japan, the Netherlands, Norway, Oman, Sweden, Singapore, Taiwan, the UK and the US. Most patients had prior hospital contact in the Indian subcontinent.
A CHP spokesman said that proper use of antibiotics and personal hygiene, especially hand hygiene, are important for the prevention of emergence and cross-transmission of NDM strains.
Ends/Thursday, June 13, 2013
Issued at HKT 19:00
NNNN
- ------
The Public Health Laboratory Services Branch (PHLSB) of the Centre for Health Protection (CHP) of the Department of Health confirmed today (June 13) a case of New Delhi metallo-β-lactamase-4 (NDM-4) Carbapenemase-producing Enterobacteriaceae in a 95-year-old man.
The patient, with chronic illnesses, travelled to India in February and developed urinary symptoms by late February. He sought local medical attention without hospitalisation. Upon arrival in Hong Kong in May he attended the Accident and Emergency Department of Queen Mary Hospital on May 26 and June 4 and no hospitalisation was required.
The clinical diagnosis was urinary tract infection. His condition has been stable all along.
The patient's urine specimen grew NDM-4 Carbapenemase-producing Enterobacteriaceae as confirmed by the PHLSB.
His family contacts remained asymptomatic. The CHP's investigation is proceeding.
This is the 28th detected case of NDM Carbapenemase-producing Enterobacteriaceae in Hong Kong.
NDM is an enzyme which can inactivate carbapenems and other beta-lactams such as penicillins. Bacteria harbouring this NDM gene are commonly resistant to multiple antimicrobials, limiting therapeutic options and rendering severe clinical infections difficult to treat. Most bacteria with the NDM enzyme remain susceptible to two types of antibiotics, colistin and tigecycline.
Infections have varied from being asymptomatic to potentially life-threatening or fatal. The level of risk depends on which part of the body is affected by the infection, and the general health of the patient.
NDM-producing Enterobacteriaceae was first reported in a Swedish patient of Indian origin who travelled to New Delhi, India, in 2008. The first fatal case was identified in 2010 in a patient who received medical treatment in Pakistan before being repatriated to Belgium.
NDM-producing Enterobacteriaceae has now been reported in many countries and regions including Australia, Austria, Canada, Belgium, France, Germany, Japan, the Netherlands, Norway, Oman, Sweden, Singapore, Taiwan, the UK and the US. Most patients had prior hospital contact in the Indian subcontinent.
A CHP spokesman said that proper use of antibiotics and personal hygiene, especially hand hygiene, are important for the prevention of emergence and cross-transmission of NDM strains.
Ends/Thursday, June 13, 2013
Issued at HKT 19:00
NNNN